Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Abt - What They Never Told You

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

DTM 2026: Full 21-car entry list

The DTM unveiled its 2026 entry list, featuring 21 cars: Check out which drivers are on this year's grid, and which are missing - plus why the field is slightly smaller than last year's

Motorsport

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Abbott Earnings Preview: What to Expect

Abbott is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Barchart

This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

Barchart

Who is Misty Copeland? The Ballerina Who Earned Timothée Chalamet's Standing Ovation at the Oscars After Ballet Backlash

Misty Copeland, the first Black woman promoted to principal dancer at American Ballet Theatre, returned to the stage at the 2026 Oscars with a performance that earned a standing ovation.

International Business Times UK

Lamborghini explains Mirko Bortolotti's move from Abt to Grasser in DTM

After a disappointing year at Abt, Mirko Bortolotti returns to Grasser as Lamborghini outlines the reasoning behind the switch involving its leading Austrian team.

Motorsport

Read news from The Economist, FT, and more,
with one subscription

Nicki Thiim on tough Lamborghini DTM years: “My head is still exploding”

Sleepless nights, a car that felt “special” and a duel with the strongest Huracan driver, Nicki Thiim speaks candidly about a difficult period in the DTM

Motorsport

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

Barchart

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

MarketBeat

What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Barchart

This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Barchart

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Barchart

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘She redefined who belongs’: Misty Copeland takes final bow with American Ballet Theatre

Copeland made history as the first Black female principal dancer in the company's 75-year existence

International Business Times UK

Miss Panama Isamar Herrera Embraces Newfound Fame After Miss Grand International 2025 Blunder

Miss Panama Isamar Herrera experienced an embarrassing moment during the Miss Grand International 2025. But, she's now embracing her newfound popularity.

International Business Times UK

Why Did Misty Copeland Quit ABT? Principal Exits ABT With No Successor in Sight—Is Ballet Still Not Ready for Black Ballerinas?

Misty Copeland ends her 25-year journey with American Ballet Theatre, questioning ballet's slow progress on diversity as no Black successor follows.

The Independent UK

Misty Copeland will take to the ballet stage one last time, before hanging up her pointe shoes

Misty Copeland is taking one last passionate spin on the ballet stage before saying goodbye

Barchart

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

MarketBeat

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

Benzinga

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

1 2 3 4 5

People

Thomas Preining Manthey

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.